EPO and triple-A syndrome: Therefore, this study aims to explore the potential association between gut microbiota changes and AAA development in this model.<h4>Methods and results</h4>Adult male C57BL/6 mice were used to establish the AAA model by intraperitoneal administration of recombinant human EPO at a dosage of 10,000 IU/kg daily for 28 consecutive days.